Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial.

Am J Transplant · 2013 · PMC3613750 · PMID 23279614

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Within groups, the reductions in total daily dose (both the mean and percent change from baseline) were highly significant in the LCPT group, whereas the Prograf group showed only slight reductions.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.